scispace - formally typeset
A

Anna-Karin Olsson

Researcher at Science for Life Laboratory

Publications -  82
Citations -  5760

Anna-Karin Olsson is an academic researcher from Science for Life Laboratory. The author has contributed to research in topics: Neutrophil extracellular traps & Histidine-rich glycoprotein. The author has an hindex of 28, co-authored 69 publications receiving 4942 citations. Previous affiliations of Anna-Karin Olsson include Uppsala University & College of Health Sciences, Bahrain.

Papers
More filters
Journal ArticleDOI

VEGF receptor signalling - in control of vascular function.

TL;DR: Recent insights have shed light onto VEGFR signal transduction and the interplay between different V EGFRs and VEGF co-receptors in development, adult physiology and disease.
Journal ArticleDOI

Consensus guidelines for the use and interpretation of angiogenesis assays

Patrycja Nowak-Sliwinska, +90 more
- 01 Aug 2018 - 
TL;DR: In vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis are described and critical aspects that are relevant for their execution and proper interpretation are highlighted.
Journal ArticleDOI

Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals

TL;DR: It is suggested that neutrophil extracellular traps mediate the negative collateral effects of tumors on distal organs, acting to impair vascular function, and to heighten inflammation at these sites.
Journal ArticleDOI

CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer

TL;DR: New light is shed on the mechanisms underlying the progression of ER+ breast cancer and the potential of novel therapies targeting CCL2 and CCL5 pathways is indicated.
Journal ArticleDOI

A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization.

TL;DR: This study shows for the first time inhibitory effects of HRGP on tumor vascularization in vivo, thus providing proof of concept that HRGP is an angiogenesis inhibitor.